In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality.

Raina Zhang,Eleftherios Mylonakis

doi:10.7326/acpj202102160-017

In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality.

Raina Zhang, Eleftherios Mylonakis

https://doi.org/10.7326/acpj202102160-017

Copy DOI

Export

Save

Cite

Journal: Annals of Internal Medicine	Publication Date: Feb 1, 2021
Citations: 18

Affiliation: Brown University, Providence College

#American College Of Physicians #Rhode Island #Ritonavir In Patients #Life-threatening COVID-19 #Lancet Respir Med #Lopinavir Ritonavir #Platform Trial #Epidemiological Impact #Viral Protease #HIV-Infected Individuals

Abstract
Full-Text
Similar Papers

Abstract

Listen

Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19-interim WHO Solidarity Trial results. N Engl J Med. 2020. [Epub ahead of print.] 33264556.

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Internal Medicine

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality.